Skip the snow and say hello to sunshine. Divi Resorts is helping travelers plan ahead and escape the winter grind with its limited-time Holiday Travel Sale, featuring up to 35% off beachfront ...

Once opened in a browser, the code decrypts a secondary payload using a static XOR key and then redirects the user to an ...

Divi's Laboratories shares rose on July 8 after brokerage firm HSBC has raised rating to "buy" and sharply increased the target price by over 50% to Rs 7,900 from earlier target of Rs 5,200.

Get detailed information about the Satrix Divi Plus ETF. View the current STXDIVJ stock price chart, historical data, premarket price, dividend returns and more.

Shares of Divi's Laboratories Ltd. gained on Tuesday, July 8, as brokerage firm HSBC upgraded its rating on the stock and raised its price target by 57%. The brokerage has upgraded its rating to "buy" ...

HSBC Global Research has upgraded Divi's Laboratories Ltd. to 'buy' rating, citing promising growth trajectory driven by its involvement in the production of anti-diabetes drug tirzepatide, other ...

Stock analysis for Divi's Laboratories Ltd (DIVI:Natl India) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Current and Historical Performance Performance for Franklin International Core Dividend Tilt Index ETF on Yahoo Finance.

Divi's Laboratories is poised to benefit from its involvement in diabetes and weight loss drugs. Devyani International's acquisition of Sky Gate Hospitality is expected to boost its QSR business, ...

Performance charts for Satrix Dividend Plus ETF (STXDIV - Type ETF) including intraday, historical and comparison charts, technical analysis and trend lines.